Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05585307 · ClinicalTrials.gov registry record · Phase 1
Study of Novel Antiretrovirals in Participants With HIV-1
A Phase 1 study of HIV-1-infection, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 20
- Study locations
NCT05585307: Completed Phase 1 study of HIV-1-infection, sponsored by Gilead Sciences.
NCT05585307 is a Phase 1 study of HIV-1-infection that has completed, run by Gilead Sciences. The registered enrollment target is 49 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05585307, a Phase 1 study of HIV-1-infection, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 20
- Study locations
Study Summary
Master protocol: The goal of this master clinical trial study is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy-01 (GS-US-544-5905-01) will evaluate bavtavirine in PWH. Substudy-02 (GS-US-544-5905-02) will evaluate GS-1720 in PWH. Substudy-03 (GS-US-544-5905-03) will evaluate GS-6212 in PWH.
Conditions Studied
Interventions
- DRUG B/F/TAF
- DRUG GS-1720
- DRUG Bavtavirine
- DRUG Standard of Care (Substudy 01)
- DRUG Standard of Care (Substudy 02)
Study Locations (20)
Florida
- Midland Florida Clinical Research Center, LLC,Substudy-02 - DeLand
- Midland Florida Clinical Research, LLC,Substudy-03 - DeLand
- Midway Immunology and Research Center,Substudy-01 - Ft. Pierce
- Midway Immunology and Research Center,Substudy-02 - Ft. Pierce
- Midway Immunology and Research Center,Substudy-03 - Ft. Pierce
- Bliss Health,Substudy-02 - Orlando
- Bliss Health,Substudy-03 - Orlando
- Orlando Immunology Center,Substudy-01 - Orlando
- Orlando Immunology Center,Substudy-03 - Orlando
California
- Long Beach Education and Research Consultants,Substudy-03 - Long Beach
- Mills Clinical Research,Substudy-02 - Los Angeles
- Mills Clinical Research,Substudy-03 - Los Angeles
- Quest Clinical Research,Substudy-01 - San Francisco
- Quest Clinical Research,Substudy-02 - San Francisco
- Quest Clinical Research,Substudy-03 - San Francisco
District of Columbia
- Washington Health Institute,Substudy-01 - Washington D.C.
- Washington Health Institute,Substudy-02 - Washington D.C.
- Washington Health Institute,Substudy-03 - Washington D.C.
Connecticut
- Yale University; School of Medicine; AIDS Program (Administrative & Study Supplies),Substudy-03 - New Haven
- Yale University,Substudy-02 - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2022-10-26 |
| Est. Completion | 2024-03-18 |
| Phase | Phase 1 |
What the finished NCT05585307 record still lists
NCT05585307 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (86% lower).
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 5 interventions - of which B/F/TAF is the first listed.
NCT05585307 names 20 study sites across 4 states, led by Florida, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05585307 about?
NCT05585307 is a clinical study titled "Study of Novel Antiretrovirals in Participants With HIV-1". Master protocol: The goal of this master clinical trial study is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy-01 (GS-US-544-5905-01) will evaluate bavtavirine...
What is the current status of trial NCT05585307?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2022-10-26. Estimated completion is 2024-03-18.
What conditions does trial NCT05585307 study?
This clinical trial studies the following conditions: HIV-1-infection.
What interventions are being tested in trial NCT05585307?
The interventions under investigation include: B/F/TAF (DRUG), GS-1720 (DRUG), Bavtavirine (DRUG), Standard of Care (Substudy 01) (DRUG), Standard of Care (Substudy 02) (DRUG).
Who is sponsoring clinical trial NCT05585307?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05585307 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05585307's enrollment target sits among peer trials
49 51st of 71 higher than 21 of 71 other HIV-1-infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV-1-infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of GS-3242 in Participants With HIV-1; Substudy-05
RECRUITING · Phase 1
-
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
RECRUITING · Phase 1
-
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
RECRUITING · Phase 1
-
Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age
RECRUITING · Phase 1
-
PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)
RECRUITING · Phase 1
-
Safety Study of MucoCept-CVN
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI